Thera-SAbDab

LEBRIKIZUMAB

> Structural Summary

Therapeutic	Lebrikizumab
Target	IL13
Heavy Chain	QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS
Light Chain	DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIK
100% seqID Fv Structure	4i77 [Fvs: HL]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	4i77 [Fvs: HL]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G4
Highest Clinical Trial (June '19)	Phase-III
Estimated Status (June '19)	Active
Recorded Developmental Technology	na
INN Year Proposed	2009
INN Year Recommended	2010
Companies Involved	Chugai Pharmaceutical, Comprehensive Clinical Research Network, Dermira, Genentech, Roche, Tanox
Conditions Approved	na
Conditions Active	Atopic dermatitis
Conditions Discontinued	Asthma, Chronic obstructive pulmonary disease, Hodgkin's disease, Idiopathic pulmonary fibrosis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]